MS Trust

Survey Results Show Impact of MS in All Aspects of Life

Multiple sclerosisĀ (MS) affects all aspects of life, from physical and mental health to relationships, and from work and finances to hobbies and holidays, according to results from an online survey conducted by the U.K.ā€™s MS Trust. Most respondents said they wanted more support to manage their fatigue, improve…

Zeposia Tablets Approved in Scotland to Treat Active RRMS

The Scottish Medicines Consortium (SMC) has approvedĀ Zeposia (ozanimod)Ā for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is sold as a tablet, to be taken by mouth once daily. The SMC has recommended that Zeposia be prescribed for people with RRMS who experience relapses or have evidence of…

Mayzent Approved for Active Secondary Progressive MS in Scotland

The Scottish Medicines Consortium (SMC) has approved Mayzent (siponimod) for the treatment of active secondary progressive multiple sclerosis (SPMS) in Scotland. Mayzent, developed by Novartis, is a tablet taken once daily to counter a person’s disability progression. SPMS gradually develops from relapsing-remitting MS, and is…

NICE Does Not Favor Adding Mayzent to NHS England for Active SPMS

TheĀ National Institute for Health and Care Excellence (NICE) is recommending againstĀ Mayzent (siponimod) as a treatment for active secondary progressive multiple sclerosis (SPMS) in the U.K., because its cost-effectiveness relative to an existing treatment for these patients is not known. NICE’s draft guidance for Mayzent is open…

NICE Approves Plegridy as RRMS Treatment Offered by NHS England

The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion of Plegridy (peginterferon beta-1a) to treatĀ relapsing-remitting multiple sclerosis (RRMS) in England within the National Health Service (NHS). This decision follows a cost-effectiveness review done in May 2018,…

Scottish Medicines Consortium Approves Ocrevus for Treating PPMS

Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS). The Scottish Medicines Consortium (SMC) has advised that OcrevusĀ can be prescribed by the National Health Service (NHS) forĀ people with PPMS who have had symptoms for less than 15…

Heavy Caseloads for MS Specialist Nurses in UK Compromise Patient Care, MS Trust Reports

Nurses who specialize in treatingĀ multiple sclerosis (MS) patients in the U.K. are handling heavier caseloads than recommended or preferred, resulting in patients going without the necessary care and support they deserve, theĀ MS TrustĀ reports. Particularly, the 2018 report notes that newer treatments require more complex and careful monitoring. However,Ā it…

MS Trust Project to Bring Needed Services to People with Advanced MS Wins October Club’s Support

The British fundraising groupĀ The October Club and The MS Trust, aĀ U.K. multiple sclerosis research and support organization,Ā have announcedĀ an ambitious planĀ toĀ potentially helpĀ thousands of advanced MS patientsĀ in need of services. Composed ofĀ people working in the financial equity industry in London, The October Club raises money for a differentĀ charity each yearĀ through…

MS Trust to Oppose NICE Plan to Reject Zinbryta as MS Therapy in Health System for England, Wales

The Multiple Sclerosis (MS) Trust isĀ expressing its disappointment at the recent committee decision ofĀ theĀ National Institute for Health and Care ExcellenceĀ (NICE)Ā to not recommendĀ Zinbryta (daclizumab) be made available as a therapy to MSĀ patients using the public health system in England and Wales. NICE’sĀ preliminary recommendationĀ was based on a review of…